Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 25, 2023 08:00 ET | Source: Revolo Biotherapeutics

Revolo Biotherapeutics Announces Data from Study of ‘1104 in Atopic Adults

- Treatment with ‘1104 demonstrated a rapid reduction in intradermal allergic inflammation - - Treatment with ‘1104 induced sustained activation of T regulatory and B regulatory cells, providing...
October 17, 2023 08:00 ET | Source: Revolo Biotherapeutics

Revolo Biotherapeutics to Present Data from Phase 2a Clinical Trial of ‘1104 in Eosinophilic Esophagitis at ACG 2023

NEW ORLEANS and CAMBRIDGE, United Kingdom, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to...
September 21, 2023 08:00 ET | Source: Revolo Biotherapeutics

Revolo Biotherapeutics Announces the Completion of Phase 1 Multiple Ascending Dose Clinical Trial of ‘1104

NEW ORLEANS and CAMBRIDGE, United Kingdom, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to...
August 08, 2023 08:00 ET | Source: Revolo Biotherapeutics

Revolo Biotherapeutics to Host Virtual KOL Event on ‘1104: A First-in-Class Peptide for Eosinophilic Esophagitis (EoE) and Allergic Disease

NEW ORLEANS and CAMBRIDGE, United Kingdom, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to...
July 18, 2023 08:00 ET | Source: Revolo Biotherapeutics

Revolo Biotherapeutics Announces Additional Data from Phase 2a Trial of ‘1104 in Adults with Active Eosinophilic Esophagitis

- Data shows statistically significant improvement in patient-reported dysphagia symptoms compared to placebo - - Unique broad mechanistic effect across a range of key cell types associated with EoE...
June 05, 2023 08:00 ET | Source: Revolo Biotherapeutics

Revolo Biotherapeutics Presents New Data for ‘1805 in Inflammatory Bowel Disease and Rheumatoid Arthritis at the 5th Treg Directed Therapies Summit

NEW ORLEANS and CAMBRIDGE, United Kingdom, June 05, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to...
May 22, 2023 08:00 ET | Source: Revolo Biotherapeutics

Revolo Biotherapeutics Presents New Preclinical Data for ‘1104 in Acute Respiratory Distress Syndrome Associated With Influenza Infection at the ATS 2023 International Conference

Data continues to demonstrate the broader potential of ‘1104 to avoid and reduce inflammation in multiple models of disease, including allergy and beyond NEW ORLEANS and CAMBRIDGE, UK,, May 22, 2023...
May 10, 2023 08:00 ET | Source: Revolo Biotherapeutics

Revolo Biotherapeutics Announces Presentations at Upcoming Medical Meetings

NEW ORLEANS and CAMBRIDGE, United Kingdom, May 10, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve...
April 19, 2023 08:00 ET | Source: Revolo Biotherapeutics

Revolo Biotherapeutics Announces Positive Topline Data from Phase 2a Trial of ‘1104 in Adults with Active Eosinophilic Esophagitis

- Data shows achievement of primary endpoint of decreasing esophageal intraepithelial eosinophil count and positive impact on an array of histological measures of EoE – - Favorable safety and...
April 13, 2023 08:00 ET | Source: Revolo Biotherapeutics

Revolo Biotherapeutics to Present at the 8th Food Allergy Fund Summit

NEW ORLEANS and CAMBRIDGE, England, April 13, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve...